Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R9VR
|
|||
| Former ID |
DAP000559
|
|||
| Drug Name |
Galantamine
|
|||
| Synonyms |
GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Approved | [1], [2] | |
| Therapeutic Class |
Parasympathomimetics
|
|||
| Company |
Janssen Pharmaceutica
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H21NO3
|
|||
| Canonical SMILES |
CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O
|
|||
| InChI |
1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
|
|||
| InChIKey |
ASUTZQLVASHGKV-JDFRZJQESA-N
|
|||
| CAS Number |
CAS 357-70-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10719, 584656, 584664, 606095, 831251, 7887946, 7979350, 8004402, 8156932, 11335765, 11361004, 11364165, 11366727, 11369289, 11372735, 11374555, 11377451, 11461976, 11466616, 11467736, 11486391, 11491553, 11492654, 11495085, 11537759, 14751181, 14775584, 24875119, 25646023, 26697250, 26751839, 29228225, 46391750, 46393027, 46505659, 46511027, 47206224, 47216757, 47216758, 47291111, 47515304, 47588978, 47885390, 47959724, 48259212, 48334469, 48334470, 49698570, 49972082, 53786839
|
|||
| ChEBI ID |
CHEBI:42944
|
|||
| ADReCS Drug ID | BADD_D00996 ; BADD_D00997 | |||
| SuperDrug ATC ID |
N06DA04
|
|||
| SuperDrug CAS ID |
cas=000357700
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides coprophilus DSM 18228 (log2FC = -0.578; p = 0.03). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.71; p = 0.002). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.67; p = 0.007). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.594; p = 0.011). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.519; p = 0.006). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.457; p = 0.01). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.563; p = 0.007). | |||
|
Studied Microbe: Bacteroides ovatus ATCC 8483
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides ovatus ATCC 8483 (log2FC = -0.494; p = 0.011). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.453; p = 0.019). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.589; p = 0.018). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.627; p = 0.004). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Galantamine can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.495; p = 0.002). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Acetylcholinesterase (AChE) | Target Info | Inhibitor | [4], [5], [6] |
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Cholinergic synapse | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | ||||
| Pathwhiz Pathway | Phospholipid Biosynthesis | |||
| Pathway Interaction Database | ATF-2 transcription factor network | |||
| WikiPathways | Monoamine Transport | |||
| Biogenic Amine Synthesis | ||||
| Acetylcholine Synthesis | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6693). | |||
| REF 2 | Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. | |||
| REF 5 | Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport. 2009 Feb 18;20(3):285-8. | |||
| REF 6 | Acetylcholinesterase inhibitors enhance cognitive functions in rats following hypobaric hypoxia. Behav Brain Res. 2009 Oct 12;203(1):1-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.